ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Defiance Daily Target 2X Long MRNA ETF
21.01
-0.3576
-1.67%
盤後:
20.99
-0.0189
-0.09%
16:47 EDT
成交量:
1.14萬
成交額:
24.78萬
市值:
231.10萬
市盈率:
- -
高:
22.60
開:
20.78
低:
20.78
收:
21.37
52周最高:
39.54
52周最低:
14.95
股本:
11.00萬
流通股本:
11.00萬
量比:
0.51
換手率:
10.34%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Replimune的皮膚癌藥物在美國獲批迎來第三次機會
路透中文
·
05/29
美國食品藥品監督管理局(FDA)顧問委員會投票讚成建議新冠疫苗針對XFG變異株
路透中文
·
05/29
美國FDA顧問投票支持建議2026-27年度新冠疫苗以Jn.1譜系Xfg變異株為靶點
美股速递
·
05/29
Moderna公司計劃於八月中旬前備妥2026-27年度推薦新冠疫苗組分供應
美股速递
·
05/28
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MRNX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNX\",,,,,undefined,":{"symbol":"MRNX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long MRNA ETF","latestPrice":21.0089,"timestamp":1780084800000,"preClose":21.3665,"halted":0,"volume":11377,"hourTrading":{"tag":"盘后","latestPrice":20.99,"preClose":21.0089,"latestTime":"16:47 EDT","volume":12,"amount":251.7778,"timestamp":1780087665104,"change":-0.0189,"changeRate":-0.0009,"amplitude":0},"delay":0,"changeRate":-0.016736480003744083,"floatShares":110000,"shares":110000,"eps":0,"marketStatus":"休市中","change":-0.3576,"latestTime":"05-29 16:00:00 EDT","open":20.78,"high":22.6,"low":20.78,"amount":247841,"amplitude":0.08518,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":21.3665,"sharesOutstanding":30000,"nav":21.37,"aum":2350700,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":21.6,"preClose":21.3665,"latestTime":"06:02 EDT","volume":407,"amount":8556.989408,"timestamp":1780048964426,"change":0.2335,"changeRate":0.010928,"amplitude":0.041654},"postHourTrading":{"tag":"盘后","latestPrice":20.99,"preClose":21.0089,"latestTime":"16:47 EDT","volume":12,"amount":251.7778,"timestamp":1780087665104,"change":-0.0189,"changeRate":-0.0009,"amplitude":0},"volumeRatio":0.5061304682875933},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNX\",,,,,undefined,":{"symbol":"MRNX","floatShares":110000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5061304682875933,"shares":110000,"dividePrice":0,"high":22.6,"amplitude":0.08518,"preClose":21.3665,"low":20.78,"week52Low":14.95,"pbRate":"--","week52High":39.535,"institutionHeld":0,"latestPrice":21.0089,"eps":0,"divideRate":0,"volume":11377,"delay":0,"ttmEps":0,"open":20.78,"prevYearClose":20.61,"prevWeekClose":20.805,"prevMonthClose":20.7722,"prevQuarterClose":26.2923,"fiveDayClose":21.292,"twentyDayClose":20.7722,"sixtyDayClose":35.4537},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRNX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRNX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRNX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MRNX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639622049","title":"Replimune的皮膚癌藥物在美國獲批迎來第三次機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2639622049","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639622049?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 20:12","pubTimestamp":1780056779,"startTime":"0","endTime":"0","summary":"更新版 4-Replimune的皮肤癌药物在美国获批迎来第三次机会重启申请的消息传出后,股价暴涨86%《华尔街日报》称白宫敦促卫生官员重新审查FDA的驳回决定 Replimune称FDA将优先审查重新提交的申请分析师指出,FDA立场转变的动因尚不明确重写第1段,在第4-5段中补充《华尔街日报》报道的细节,第6段尝试获取评论,最后为股价及要点。路透5月30日 - Replimune公司周五表示,在与美国监管机构达成协议后,计划于未来数日第三次申请其实验性皮肤癌药物的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4S42613K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","IE0009355771.USD","SRPU","LU0432979614.USD","IE0002141913.USD","LU1718418525.SGD","LU0225771236.USD","LU2125154935.USD","LU1261432733.SGD","LU0868494617.USD","BK4007","LU1868836914.USD","BK4559","BK4588","LU1571399168.USD","LU1093756325.SGD","LU0237698245.USD","LU2242652126.USD","LU0114720955.EUR","LU0306806265.USD","MRNA","LU1430594728.SGD","LU0061475181.USD","SRPT","LU1868836757.USD","IE00BJJMRZ35.SGD","REPL","BK4534","BK4568","LU1983299246.USD","MRNX","MRNY","LU1670710661.SGD","LU1868836591.USD","BMY","LU1670711040.USD","LU1032466523.USD","IE00BFXG1179.USD","BK4501","LU1868837300.USD","LU1074936037.SGD","LU1883839398.USD","BK4532","BK4551","LU1670711123.USD","LU0321505868.SGD","LU2242646821.SGD","BK4548","LU0096364046.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639961878","title":"美國食品藥品監督管理局(FDA)顧問委員會投票讚成建議新冠疫苗針對XFG變異株","url":"https://stock-news.laohu8.com/highlight/detail?id=2639961878","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639961878?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 02:30","pubTimestamp":1779993056,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)顾问委员会投票赞成建议新冠疫苗针对XFG变异株路透5月28日 - 美国食品药品监督管理局(FDA)的咨询委员会周四投票通过了一项建议,即2026-2027年度免疫接种活动所使用的新冠疫苗应针对占主导地位的JN.1谱系XFG变异株。九名委员会成员中有八人投票支持该建议,一人弃权。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4T4251VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","MRNX","LU0058720904.USD","SG9999002232.USD","LU1066051498.USD","IE00BBT3K403.USD","BK4548","BK4592","IE00B19Z3581.USD","LU0234572021.USD","LU0456855351.SGD","LU1023059063.AUD","BK4551","BK4581","LU1066053197.SGD","SG9999003800.SGD","SG9999011175.SGD","IE0002270589.USD","SGXZ57979304.SGD","IE000M9KFDE8.USD","SG9999013999.USD","IE00BLSP4239.USD","BK4501","LU0225284248.USD","BK4534","LU0225771236.USD","LU0321505439.SGD","SG9999002224.SGD","BK4532","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU0868494617.USD","PFE","SG9999001176.SGD","BK4568","LU0321505868.SGD","LU0306806265.USD","LU1057294990.SGD","BK4588","LU0306807586.USD","BK4533","LU1883839398.USD","LU1894683348.USD","MRNA","LU1894683264.USD","SG9999001176.USD","LU0170899867.USD","LU0985481810.HKD","BK4599","BK4139","BK4007","BK4585","LU0289739699.SGD","MRNY","BK4550","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139235440","title":"美國FDA顧問投票支持建議2026-27年度新冠疫苗以Jn.1譜系Xfg變異株為靶點","url":"https://stock-news.laohu8.com/highlight/detail?id=1139235440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139235440?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 02:28","pubTimestamp":1779992883,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的疫苗顾问小组已投票支持一项建议,即在2026-2027年度的新冠疫苗接种活动中,应将疫苗的靶点更新为当前流行的Jn.1谱系Xfg变异株。这一决定标志着公共卫生机构在应对病毒持续演变方面迈出了关键一步。相关企业可能需要据此调整其疫苗成分,以符合新的公共卫生指导。随着病毒变异,疫苗的定期更新已成为新常态,以确保其防护效力。最终决定权仍在FDA,但通常其会采纳顾问委员会的建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","IE00B3T34201.USD","LU1066051498.USD","BK4532","LU1057294990.SGD","LU0122379950.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU0058720904.USD","MRNY","SG9999002224.SGD","BK4550","LU0289739699.SGD","BK4585","IE00BLSP4239.USD","BK4548","BK4592","BK4581","BK4568","BK4534","SG9999001176.USD","BK4007","LU0321505439.SGD","IE00BBT3K403.USD","BK4547","BK4588","LU0306807586.USD","SG9999002232.USD","LU0306806265.USD","IE0002270589.USD","LU0985481810.HKD","MRNX","PFE","IE00B19Z3B42.SGD","BK4139","IE00BLSP4452.SGD","SG9999013999.USD","LU0321505868.SGD","LU1066053197.SGD","SG9999003800.SGD","LU1894683264.USD","LU1894683348.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU0868494617.USD","MRNA","BK4501","BK4599","BK4533","NVAX","LU0234572021.USD","LU1023059063.AUD","BK4551","LU1883839398.USD","SG9999011175.SGD","IE00B19Z3581.USD","LU0456855351.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158347106","title":"Moderna公司計劃於八月中旬前備妥2026-27年度推薦新冠疫苗組分供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1158347106","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158347106?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 20:19","pubTimestamp":1779970758,"startTime":"0","endTime":"0","summary":"根据最新简报文件披露,Moderna公司已做好充分准备,预计将在八月中旬之前完成针对2026-27年度推荐新冠疫苗组分的生产供应部署。这一时间节点对于确保秋季疫苗接种计划的顺利推进具有关键意义,显示出该公司在应对公共卫生需求方面的前瞻性布局能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4533","BK4534","BK4548","BK4139","BK4585","MRNY","BK4532","BK4588","BK4501","MRNX","MRNA","BK4551"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":24,"pageCount":1,"totalSize":93,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MRNX\",params:#limit:6,delay:false,,,undefined,":[]}}